New combo aims to free CLL patients from lifelong medication

NCT ID NCT06958705

First seen Dec 10, 2025 · Last updated May 24, 2026 · Updated 19 times

Summary

This study tests whether adding venetoclax to standard BTK inhibitor therapy can help people with chronic lymphocytic leukemia (CLL) stop all treatment after a set period. About 79 adults who have been on a BTK inhibitor for at least 6 months will receive both drugs for 12 cycles, then stop both and be monitored. The goal is to achieve undetectable cancer levels in the bone marrow, potentially allowing a break from continuous therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) / SMALL LYMPHOCYTIC LYMPHOMA (SLL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital

    RECRUITING

    Nanjing, Jiangsu, 210029, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.